Searchable abstracts of presentations at key conferences in endocrinology

ea0090p1 | Adrenal and Cardiovascular Endocrinology | ECE2023

Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia

Newfield Ron , Sarafoglou Kyriakie , Fechner Patricia Y. , Nokoff Natalie J. , Auchus Richard , Vogiatzi Maria , Giri Nagdeep , Roberts Eiry , Sturgeon Julia , Chan Jean L. , Farber Robert

Introduction: Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a rare autosomal recessive disorder characterized by deficiency of cortisol and oftentimes aldosterone, with elevated adrenocorticotropic hormone (ACTH) and steroid precursors that are shunted toward excess androgen production. A phase 2 study of adults with classic 21OHD demonstrated that crinecerfont–an oral, non-steroidal, selective corticotropin-releasing factor type...

ea0099p225 | Adrenal and Cardiovascular Endocrinology | ECE2024

Baseline characteristics of children and adolescents with classic congenital adrenal hyperplasia enrolled in CAHtalyst pediatric, a phase 3 Study of Crinecerfont, a corticotropin-releasing factor type 1 receptor antagonist

Sarafoglou Kyriakie , Kim Mimi , Lodish Maya , Felner Eric , Martinerie Laetitia , Nokoff Natalie J. , Clemente Maria , Fechner Patricia Y. , Vogiatzi Maria , Speiser Phyllis , Sturgeon Julia , Roberts Eiry , Jeha George , Chan Jean L. , Farber Robert

Objective: To describe the baseline characteristics of individuals enrolled in CAHtalyst Pediatric (NCT04806451), a randomized, double-blind, placebo-controlled, Phase 3 study evaluating the safety and efficacy of crinecerfont (a corticotropin-releasing factor type 1 receptor [CRF1] antagonist) in children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD CAH).Methods: Key eligibility criteria...